- $20.93bn
- $32.87bn
- $14.30bn
Viatris raises annual profit forecast on branded drug strength
Viatris climbs after raising lower end of annual revenue forecast
Viatris Q2 profit beats on growth in new product sales
Brief: Viatris Q2 Adjusted EPS USD 0.69 Vs. IBES Estimate USD 0.6
Viatris Inc expected to post earnings of 60 cents a share - Earnings Preview
Merck licenses experimental HIV pill to generic makers in 129 countries (updated)
India's Biocon gains after block deal
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows (updated)
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Viatris - Enters Amended And Restated Term Loan Credit Agreement On July 1, 2026 - SEC Filing
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Pfizer dismissed from US states' drug price-fixing lawsuit (updated)
Pfizer dismissed from US states' drug price-fixing lawsuit
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain
U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
Viatris beats quarterly estimates on China strength, branded drug sales (updated)
U.S. STOCKS ON THE MOVE-Albemarle, Howmet, Travere Therapeutics